NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
The Netherlands Cancer Institute
Australian and New Zealand Urogenital and Prostate Cancer Trials Group